Dual-Action Nanoparticles Target Atherosclerosis by Fixing Autophagy and Clearing Inflammatory DNA
A new nanoparticle system delivers rapamycin and a DNA scavenger directly to arterial plaques, cutting inflammation and improving plaque stability in mice.
Summary
Atherosclerosis is driven largely by unchecked inflammation inside arterial plaques. A key problem: plaques have defective autophagy, meaning cells can't clean up debris properly. When those damaged cells die, they release cell-free DNA (cfDNA) that triggers even more inflammation. Researchers at Sichuan University engineered a smart nanoparticle called R@PS45 that carries two therapeutic agents — rapamycin, which restores autophagy, and a synthetic DNA scavenger — directly into plaques. The system activates in response to the plaque's unique chemical environment. In ApoE-knockout mice, a standard atherosclerosis model, treatment significantly reduced plaque size, lowered blood levels of cfDNA and inflammatory proteins, and made plaques more stable. This two-pronged approach targets inflammation at multiple steps simultaneously.
Detailed Summary
Atherosclerosis remains the leading cause of heart disease worldwide, and controlling the inflammation that drives plaque growth is a central therapeutic goal. Two underexplored contributors to that inflammation are autophagy dysfunction and the accumulation of cell-free DNA — both of which this study addresses simultaneously with a single engineered nanoparticle platform.
Researchers designed a nanodrug delivery system called R@PS45 that encapsulates rapamycin and a cationic DNA-scavenging polymer called d-PSn. The nanoparticle is engineered to be responsive to the specific microenvironment of atherosclerotic plaques, which are characterized by elevated reactive oxygen species and mild acidity. These triggers cause the nanoparticle to release its cargo precisely where it is needed, minimizing systemic exposure.
Rapamycin, a well-known mTOR inhibitor and autophagy inducer, repairs the defective autophagy machinery inside plaque macrophages and foam cells. This prevents cells from progressing to necrosis. In parallel, d-PSn scavenges cfDNA released by dying cells before it can activate intracellular DNA sensors such as cGAS-STING, which would otherwise amplify the inflammatory cascade. Critically, the nanoparticle itself can enter cells, capture cfDNA, and shuttle it to lysosomes for degradation — a process enhanced by the autophagy that rapamycin simultaneously induces.
In ApoE-knockout mice fed a high-fat diet, R@PS45 substantially reduced aortic plaque burden, lowered circulating cfDNA and pro-inflammatory cytokine levels, and increased plaque stability markers compared to controls.
The clinical implications are significant: combining autophagy restoration with cfDNA clearance represents a mechanistically rational dual strategy for atherosclerosis. That said, results are preclinical only, and translation to humans requires pharmacokinetic, safety, and efficacy studies in larger models. This summary is based on the abstract alone.
Key Findings
- R@PS45 nanoparticles deliver rapamycin and a DNA scavenger directly to atherosclerotic plaques in a ROS- and pH-triggered manner.
- Rapamycin restores defective autophagy in plaque cells, reducing necrosis and inflammatory progression.
- The DNA scavenger d-PSn neutralizes cell-free DNA, blocking activation of inflammatory DNA sensors like cGAS-STING.
- ApoE-knockout mice treated with R@PS45 showed markedly reduced aortic plaque burden and lower inflammatory cytokines.
- The nanoparticle system improved plaque stability, a key predictor of heart attack risk.
Methodology
The study used ApoE-knockout (ApoE-/-) mice fed a high-fat diet, a standard preclinical model of atherosclerosis, to evaluate therapeutic efficacy. R@PS45 nanoparticles were characterized in vitro for ROS- and pH-responsive drug release, and plaque outcomes were assessed via aortic plaque burden, serum biomarkers, and stability indices.
Study Limitations
All efficacy data are from an ApoE-knockout mouse model; human translation will require extensive pharmacokinetic, toxicity, and large-animal studies. Long-term safety of the cationic polymer d-PSn and the nanoparticle carrier has not been established. This summary is based on the abstract only, as the full text was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: